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Cardiovascular disease (CVD) is a serious disease, and is the leading cause of 
death in the United States.  Aging and physical inactivity are two well-established risk 
factors for CVD. Previous research has identified circulating angiogenic cells (CACs) as 
a novel risk factor for CVD. CAC number and function are affected by aging and 
exercise. Nitric oxide (NO) and reactive oxygen species (ROS) are intracellular 
compounds which can affect the health of the vasculature and are also affected by 
exercise. Endothelial nitric oxide synthase (eNOS) is responsible for NO production 
within the endothelium, and eNOS  “coupling” is a phenomenon that plays a role in the 
balance between production of ROS and NO. The literature also indicates that NO can be 
produced in either a pathological or physiological capacity depending on which isoform 
of NOS produces it. NO and ROS have been previously measured in CACs and have 
	  
been shown to affect in vivo and in vitro outcomes related to vascular function. Although 
NO, ROS, and CACs have all been studied in relation to exercise, no previous studies 
have examined how the cessation of training in older endurance-trained athletes affects 
these intra-cellular compounds through the eNOS-coupling pathway. The purpose of this 
study was to examine the effect of a 10-day cessation of exercise training in older 
endurance-trained athletes on ROS, NO and the eNOS-coupling pathway in CD34+ cells. 
NO and ROS were measured in isolated fresh CD34+ cells using fluorescent dye assays. 
The mRNA expression of genes involved in the eNOS-coupling pathway (endothelial 
nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), dihydrofolate 
reductase (DHFR), and guanosine triphosphate cyclohydrolase 1 (GTPCH1)) were 
measured using semi-quantitative Polymerase Chain Reaction (Semi-qt PCR). Flow 
mediated dilation was measured to gain information about endothelial function. No 
significant differences were detected after the cessation of training in CD34+ intracellular 
NO or ROS levels. Flow mediated dilation (FMD) also did not change significantly 
following cessation of training. eNOS mRNA expression was significantly lower 
following cessation of training but iNOS, DHFR, and GTPCH1 did not change. Taking 
into consideration the current literature, we expected to see changes in all of the above 
variables with the cessation of exercise training. There were several limitations present in 
our study, which could have affected our outcomes. Research in this area, specifically the 
eNOS coupling pathway, is still very new and this study shows that additional research is 
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Chapter 1: Introduction: 
Cardiovascular disease (CVD) is the number one cause of death in the United 
States and accounted for nearly ¼ of American deaths in 2010 (Murphy et al 2013). 
Many Americans have adopted a sedentary lifestyle and as our population ages, the risk 
of developing CVD increases.  Over 30% of the adult population in the U.S. report that 
they don’t take part in any leisure time activity (Barnes 2012).  This is especially 
troubling when it is well known and accepted among the scientific community that the 
incorporation of physical activity into a person’s lifestyle can substantially reduce all-
cause mortality (Blair et al 1995). 
Researchers have established several major risk factors for developing CVD, 
including smoking, high cholesterol, sedentary lifestyle and age. This study will focus on 
the effects of aging and exercise (or lack thereof).  While the academic community agrees 
that sedentary behavior and aging are risk factors for developing CVD, current research 
must focus on the underlying mechanisms contributing to risk. Understanding the 
underlying pathology can lead to important advances in therapeutic approaches. 
Mechanistic data have expanded over the past ten years and the vasculature continues to 
be an important area to investigate in relation to the risk factors of sedentary behavior and 
aging. 
Optimally functioning blood vessels play a critical role in cardiovascular health. 
The risk factors discussed above can have a direct impact on important vascular functions 
such as vasodilation and vasoconstriction. When the vasculature is negatively affected by 
one of these risk factors, diseases such as hypertension can arise. One major risk factor 
which can adversely affect a person’s blood pressure is sedentary behavior. The SUN 
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cohort study prospectively examined the association between sedentary lifestyle and 
hypertension in middle-aged participants (Beunza et al 2007). They concluded that 
interactive sedentary behaviors (driving or computer use), were positively associated with 
incidence of hypertension. The SUN cohort study results suggest that individuals who 
lead a sedentary lifestyle, are at increased risk for hypertension (Beunza et al 2007). 
Conversely, physical activity is known to reduce blood pressure, and can be an effective 
treatment for hypertension.  A review by Hagberg et al (2000) stated that exercise 
training can reduce blood pressure in about ¾ of hypertensive patients. Additionally, low 
intensity training was found to be sufficient to elicit such changes, making this 
information very clinically relevant (Hagberg et al 2000).  Thus, regular physical activity 
is essential to maintaining optimally functioning blood vessels. 
The endothelium plays an important functional role within the vasculature. One of 
its primary roles is to control the tone of blood vessels through its release of relaxing and 
contracting factors (Vanhoutte 1996). The balance of these factors can be negatively 
affected in pathological states such as hypertension (Puddu et al 2000).  Given its direct 
impact on hypertension, it is not surprising that exercise also plays a role in endothelial 
function. Endothelium-dependent dilation is often used as a measure of endothelial 
function, given its importance in maintaining blood pressure homeostasis and the flow of 
blood through the vessels.  Clarkson et al (1999) examined the effects of a combined 
anaerobic and strength training program (10 weeks) on endothelial function in young 
healthy men.  They found that endothelium dependent dilation was significantly 
improved in the men who took part in the 10-week exercise training, when compared to 
the control group. Hambrecht et al (2000) examined the effect of exercise training on 
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endothelial function in patients with coronary artery disease. They utilized acetylcholine-
induced vasoconstriction to measure the effects of a 4-week exercise training program.  
Four weeks of exercise training caused a significant improvement in coronary endothelial 
function (Hambrecht et al 2000). If exercise can improve endothelium-dependent 
outcomes, which are typically negatively altered in cardiovascular disease states, delving 
deeper into the mechanisms at play could lead to important therapeutic information. 
Current research is heavily focused on molecular, biochemical and circulating factors, 
which could play an important role in this phenomenon. 
Circulating angiogenic cells (CACs) are circulating adult stem cells, originating 
from the bone marrow, which have been shown to have potent angiogenic, proliferative, 
and vascular repair properties (Van Craenenbroeck et al 2010).  Endothelial progenitor 
cells (EPCs) are a type of CAC, and the terms CAC and EPC are often used 
interchangeably. For our purposes, CACs and EPCs will both be viewed as circulating 
cells with angiogenic/progenitor properties.  The number of CACs in circulation and their 
function has been identified as a novel risk factor for cardiovascular disease (Hill et al 
2003).  In populations free of disease, the level of circulating EPCs was shown to be a 
better predictor of functional vascular health than traditional risk factors (Hill et al 2003).  
CD 34+ cells are one subset of circulating angiogenic cells, which have been shown to 
have specific endothelial properties (Peichev 2000).  Due to their direct relationship with 
the endothelial cell lineage, CD34+ cells are believed to have potent repair and 
angiogenic properties in the endothelium (Yang et al 2011). As a whole, circulating 
angiogenic cells have been studied extensively in relation to known cardiovascular 
disease factors such as age and sedentary behaviors. 
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Aging has been demonstrated to affect the function and number of CACs.  In a 
study on 8 young men and 8 older men, it was found that older age was associated with a 
lower number of circulating EPCs (Thijssen 2006.) Schedubel et al (2003) also found 
lower numbers of EPCs mobilized to the blood in older patients, independent of risk 
factors such as hypertension, diabetes, male gender, or ventricular function.  The number 
of CACs in circulation, while important to physiological outcomes, is not the only factor 
related to age. Research has also shown changes in CAC function with aging. Heiss et al 
(2005) examined age-related differences in the functional measure of flow mediated 
dilation (FMD) and it’s association with the number and function of EPCs.  They found 
that older men and women had significantly lower FMD, indicating underlying 
endothelial dysfunction.  They also found that although the numbers of EPCs were not 
different between young and older men and women, the capacity of EPCs to migrate, 
proliferate and survive was impaired in the older group (Heiss et al 2005). This study 
illustrates that even if the number of cells in circulation is not reduced, their functional 
differences can still affect vascular health in an aged population. Hoetzer et al (2006) also 
found decreased migratory capacity in older vs. middle-aged and young men, despite 
comparable numbers of EPCs. 
Lack of exercise or sedentary behavior is another commonly known 
cardiovascular disease risk factor, which, like aging, is associated with decreases in CAC 
number and function. Both acute and chronic exercise have been shown to result in 
changes in CAC number and function. Steiner et al (2005) investigated whether exercise 
training affected EPCs in patients with cardiovascular disease risk and coronary artery 
disease. In their twenty participants, they found that after 12 weeks of supervised running 
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they exhibited a significant increase in the number of EPCs. Their observed increase in 
EPCs was directly correlated with a change in flow-mediated dilation (Steiner et al 2005).  
Another group assessed the effects of exercise training on EPCs in patients with chronic 
heart failure. They found that after 8 weeks of supervised aerobic training, participants 
had increased levels of circulating EPCs. The participants also had an increase in the 
angiogenic cell mobilizing factors, vascular endothelial growth factor (VEGF), and 
stromal-derived factor 1 (SDF-1), present in their plasma (Sarto et al 2007).  Training 
status can also affect the way that EPCs respond to an acute exercise stimulus. Jenkins et 
al (2009) found that after 30 minutes of endurance exercise at 75% of VO2max 
(throughout), endurance-trained men saw an increase in EPCs while untrained men did 
not. This observation took place despite the two groups having similar levels of EPCs 
prior to the exercise bout. 
Just as exercise training and acute exercise can increase CAC number and 
function, cessation of exercise in previously-trained individuals can also affect the CAC 
population. Witkowsi et al (2010) studied a group of men with a history of 30 or more 
years of moderate or greater intensity exercise. The men took a 10-day break in their 
training and changes in CD34+ cell population were measured. The CD34+ cell 
population decreased by 44% after 10 days without training and these changes were 
directly correlated with changes in forearm blood flow measures. 
To summarize to this point, researchers have shown that both age and exercise 
can affect the number and behavior of circulating angiogenic cells and EPCs. Exercise 
increases the number of cells in circulation, while sedentary behavior is linked to a lesser 
number of cells in circulation (Thijssen et al 2009). While the number of cells in 
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important, the behavior of these cells has become a topic of great interest. Not only have 
older, diseased, and sedentary individuals been shown to have a lesser number of cells in 
circulation, but the cells from these populations also behave differently in vitro. Cells 
from these compromised populations exhibit decreased angiogenic properties and 
depressed function.  The proper function of CACs is important because of their 
involvement in angiogenesis, repair, and adequate vascular function. 
With the discovery of CACs and their role in healthy cardiovascular function, the 
biomedical community has begun to use these cells in therapeutic interventions. 
Autologous stem cell transplants present a viable option for therapy in individuals with 
vascular disease. Removing CACs, purifying them from the blood, and injecting the 
purified product into the same individual, as a bolus, is an excellent way to deliver 
angiogenic stem cells to injured areas without a resultant immune response. However, it 
soon became apparent that taking cells from an aged or diseased patient and re-injecting 
them in a bolus was not having the hypothesized beneficial effect. The demonstrated 
depressed function in CACs from older and diseased individuals presents a clear 
challenge for the development of autologous stem cell transplant as a therapy. 
Heeschen et al (2004) found that bone marrow mononuclear cells, including 
CD34+ cells, from patients with chronic ischemic heart disease exhibited reduced 
neovascularization in vivo when compared to cells isolated from healthy controls.  The 
Heeschen group also saw decreased migratory and colony-forming behaviors in bone 
marrow mononuclear cells from individuals with chronic ischemic heart disease. A recent 
study by Cogle et al (2014) examined bone marrow cells following acute myocardial 
infarction (AMI). Their group found that following an AMI, the percentage of CD34+ 
	  
	   7	  
cells was decreased and a decreased capacity to form endothelial colonies was also 
present.  The group performed bone marrow cell therapy and found a positive correlation 
between CD34+ percentage, and left ventricular ejection fraction (Cogle et al 2014).   
The experiments performed by the Cogle group demonstrate depressed CAC function in 
diseased patients, and the ability of CD34+ bone marrow cell therapy to partially rescue 
left ventricular ejection fraction. These results underline the need to understand the 
function of CACs in pathological conditions and mechanisms that can be targeted to 
increase function. 
Previous to the Cogle study above, autologous stem cell transplantation in AMI 
patients was studied in clinical trials. The Cardiovascular Cell Therapy Research 
Network (CCRTN) of NIH funded a series of clinical trials on this topic.  The TIME 
trials were designed to evaluate if the time elapsed between AMI and transplantation of 
bone marrow stem cells to be used in the transplant played a role in determining outcome. 
One of these clinical trials randomized patients to receive cell aspiration therapy 3 or 7 
days following AMI. The researchers found that neither the 3 day nor 7 day post AMI 
treatment yielded positive results on left ventricular function (Traverse et al 2012).  A 
second clinical trial within TIME, called LateTIME, examined autologous stem cell 
transplants 2-3 weeks following AMI to examine if a longer time elapsed following AMI 
before stem cell therapy would make a difference in outcome. Similar to the previous 
study, LateTIME also did not see any improvement in left ventricular function in patients 
with stem cell therapy 2-3 weeks following AMI when compared with those receiving 
placebo reperfusion (Traverse et al 2011). The results of recent studies on autologous 
stem cell transplants from diseased patients highlight CAC functional differences 
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between populations, and serve to illustrate the need for further research in this area to 
optimize potential therapeutic applications. 
The differences in CAC behavior among different populations, which have been 
described above, have sparked new research in the pathways and mechanisms that could 
be contributing to such differences. Many researchers have looked to long-known factors 
contributing to vascular function to answer these questions. Nitric oxide (NO) is known 
as a potent vasodilator and contributor to vascular health. NO was first identified in 1989 
by Furchgott et al, and was originally called “endothelium-derived relaxing factor.” 
Furchgott and his group realized that when they were preparing rat aorta samples, if they 
rubbed the intimal surface, which removed endothelial cells, the relaxing response of the 
artery was lost (Furchgott and Vanhoutte 1989).  Since its discovery, NO has been found 
to be involved in numerous aspects of vascular health. A review in Hypertension by 
Green et al (2013) concluded that flow-mediated dilation is, indeed, influenced by the 
presence of NO.  This finding was important, as flow-mediated dilation is a functional 
measure of vascular health. 
NO also plays an important role in vascular health by reducing platelet adherence 
and cell growth within the vessel wall (Fukai 2007). Myazaki et al (1999) examined the 
role of a NO synthase inhibitor (ADMA) in atherosclerosis. Their results showed that 
increased ADMA levels (indicating NO inhibition) were directly correlated with the 
thickness of the carotid intima-media, as well as increased arterial pressure and glucose 
intolerance (Myazaki et al 1999). Carotid intima-media thickness is often measured as an 
indication of the presence of atherosclerotic cardiovascular disease. As demonstrated 
above, if NO is not released from the endothelium, pathological conditions leading to 
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atherosclerosis can occur. Smooth muscle proliferation, leukocyte adhesion, and 
endothelial injury are some of the pathological conditions caused if the endothelium fails 
to release NO (Dusting et al 1998). 
NO has also been shown to play a role in CACs. Ward et al (2011) conducted a 
series of experiments using endothelial NO synthase (eNOS) gene transfer experiments in 
CACs from coronary artery disease (CAD) patients and healthy controls to determine the 
role of NO in CAC function. eNOS gene transfer successfully increased nitric oxide 
levels in CACs.  Their findings indicated that eNOS gene transfer in CACs from the 
CAD patients, due to increased NO levels, increased chemotactic migration and 
angiogenic tube formation in vitro. They also performed in vivo experiments to measure 
changes in neovascularization and ischemic hind-limb perfusion. In vivo, CACs from the 
CAD patients with eNOS gene transfer exhibited higher levels of NO, a greater ability to 
neovascularize, and improved ischemic hind-limb reperfusion. With eNOS gene transfer, 
in vivo neovascularization and ischemic hind limb reperfusion was almost completely 
rescued in the cells from CAD patients when compared to CACs from healthy controls. 
(Ward et al 2011).  Mangialardi et al (2011) examined the effects of NO-donating 
atorvastatin on CACs. CACs from healthy volunteers and type-2 diabetic patients were 
examined.  They cultured the CACs under both high glucose and low glucose conditions. 
The high glucose condition impaired migration, proliferation and outgrowth. Impaired 
function from high glucose conditions was rescued by NO-donating atorvastatin. They 
also saw improvement in function of CACs from type-2 diabetic patients with the 
addition of NO-donating atorvastatin (Mangialardi et al 2011). 
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NO is produced by NO synthase (NOS), of which several isoforms have been 
identified. Each isoform of NOS plays a different role in the balance of vascular health.  
NO can be measured globally, which is an overall measure of NO produced by all of the 
isoforms of NOS. However, which NOS isoform the NO is being produced by can 
provide insight into the pathway the NO will follow and what mechanisms it is involved 
in (Wilcox et al 1997). In this study we will focus on two forms of NOS:  endothelial 
NO/NOS III (eNOS) and inducible NO/ NOS II (iNOS). 
Endothelial NO synthase (eNOS), as indicated by its name, is responsible for the 
production of NO in endothelial cells. Aicher et al (2003) also demonstrated that eNOS 
plays a role in the mobilization of EPCs.  They found that eNOS knockout mice had a 
diminished ability to mobilize EPCs from the bone marrow (Aicher et al 2003).  
Recently, it was discovered that the production of NO within endothelial cells by eNOS 
is the result of an important balance in vascular homeostasis called “eNOS coupling”. 
When eNOS is “coupled”, it produces NO to maintain vascular health.  When eNOS 
becomes “uncoupled” endothelial dysfunction occurs due to an increased production of 
reactive oxygen species (ROS) and decreased production of bioavailable NO (Yang et al 
2009).  While low levels of ROS may be important to activate protective pathways, ROS 
in excess can lead to impaired vessel repair and angiogenesis (Fleisner and Thum 2011).  
High levels of endothelial ROS are present in many disease conditions, such as 
hypertension and cardiovascular disease (Schiffrin 2010). As discussed previously, aging 
and exercise are two risk factors that can affect vascular health. These risk factors also 
play a role in eNOS expression and function.  Tanabe et al (2003) examined this 
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phenomenon in the rat aorta and found that exercise training can partially rescue the 
decreased expression of eNOS in aged rats. 
Since the coupling of eNOS is such a delicate balance, cofactors are thought to 
play an important role. Tetrahydrobiopterin (BH4) is a cofactor largely responsible for 
the coupling of eNOS. When levels of BH4 are reduced, eNOS becomes uncoupled and 
begins to produce ROS in excess (Xie et al 2010). BH4 also plays an important role in 
endothelium dependent dilation (EDD), due to its role in endothelial NO bioavailability.  
Eskurza et al (2005) showed that BH4 is directly involved in age-impaired EDD.  They 
demonstrated that BH4 could be a key factor in age-impaired EDD and that it could also 
be involved in the protective effect of exercise training on EDD.  As Eskurza et al 
suggest, BH4 has been shown to be affected by age and exercise training status.  With 
age, levels of BH4 decrease; however, habitual exercise can prevent this decrease and 
preserve NO bioavailability (Rush 2009).  BH4 can also be oxidized to BH2 by ROS, 
also contributing to eNOS uncoupling and reduced NO bioavailability.  This can lead to a 
vicious cycle of BH4 oxidation to BH2, eNOS uncoupling with increased ROS 
production, and further oxidation of BH4 due to peroxynitrite formation from eNOS 
uncoupling (Fuaki 2007). 
GTP Cyclohydrolase I (GTPCH1) is the rate-limiting enzyme in the de novo 
production of BH4. Dihydrofolate reductase (DHFR) catalyzes the recycling pathway 
responsible for the conversion of BH2 back to BH4.  Both of these enzymes are essential 
for the production and function of BH4 and, therefore, the coupled function of eNOS.  
Shear stress increases GTPCH1 activity and, as a result, BH4 levels (Pall 2009).  Widder 
et al (2007) demonstrated this in vitro by inducing laminar shear stress on human 
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endothelial cells.  They saw increases in both BH4 and GTPCH1 with laminar shear 
stress induction. DHFR is directly involved in the maintenance of the BH4 to BH2 ratio. 
This ratio can provide insights into vascular health.  In fact, the ratio between BH4 and 
BH2, when tipped in the direction of BH2, can indicate eNOS uncoupling (Crabtree et al 
2008). Since DHFR is responsible for the salvaging pathway that can reduce BH2 back to 
BH4, understanding how risk factors affect DHFR is critical. 
Inducible NO is believed to be responsible for the pathological production of NO 
rather than the physiological production of NO by its counterparts, such at eNOS. Unlike 
eNOS, which produces NO for short periods of time when activated, iNOS produces NO 
for an extended period of time (Kroncke et al 1998). iNOS has been found to be active 
during cardiac events, inflammatory disease states, and other pathologic conditions 
(Kroncke et al 1998).  iNOS is also believed to be involved in the production of 
peroxynitrite, a harmful reactive nitrogen species (Buttery et al 1996). 
When NO is measured globally, it is difficult to discern if the NO present is being 
produced pathologically or physiologically. In some studies higher levels of NO can be 
found in higher risk groups, and cause confusion among researchers as to the exact role 
nitric oxide is playing.  It is important to make a distinction between pathological vs. 
physiological production of NO in order to fully understand the mechanisms at play. 
Jenkins et al (2011) measured NO, iNOS, and eNOS in PBMCs from both sedentary and 
exercise trained men.  Surprisingly they found higher levels of NO in the PBMCs from 
the sedentary men when compared to the exercise trained men.  However, they also found 
higher levels of superoxide in the sedentary men. Upon further examination, they found 
that the sedentary group’s iNOS mRNA levels were two-fold higher than the men in the 
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trained group. They also found that eNOS mRNA levels in the sedentary group were 50% 
lower than the trained men (Jenkins et al 2011). Examining the levels of eNOS and iNOS 
gave them extremely important insights into pathological vs. physiological NO 
production in their participants and elucidated mechanistic information that otherwise 
might have been overlooked. 
In summary, exercise and aging are commonly accepted as important risk factors 
for cardiovascular disease. As science advances, research is beginning to shed light on 
the pathways and mechanisms involved in these risk factors at a cellular level. Research 
has identified circulating angiogenic cells (CACs) as playing an important role in these 
pathways at the cellular level. CACs are affected by age and exercise in a variety of 
ways, including their production of NO  and ROS. The phenomenon of eNOS 
coupling/uncoupling presents an important mechanism in the homeostatic functioning of 
CACs. Studies have been conducted relative to age, exercise, NO, and eNOS coupling in 
a variety of contexts, but we propose to combine these factors in a single study on 








Hypothesis: In a group of long-term endurance-trained men and women athletes, a ten-
day cessation of training will lead to an increase in pathological production of NO and 
ROS levels in CD34+ CACs, through the eNOS-uncoupling pathway. 
Specific Aim 1: Measurement of NO and ROS in CD34+ cells at baseline and following 
cessation of training, using fluorescent assays. 
Specific Aim 2: Flow-mediated dilation measurements in participants at baseline and 
following cessation of training to be used as a functional measure of NO bioavailability. 
Specific Aim 3: mRNA expression measurement of eNOS, iNOS, DHFR, and GTPCH1 













Chapter 2: Methods 
Participants: 
Participants were endurance-trained “Master athletes.” Master Athlete was 
defined as taking part in exercise for at least four hours a week at high intensity, for at 
least 15 continuous years, and being between the ages of 50 and 80 years old. They were 
recruited from the local area including local running clubs and organizations.  They had 
participated in exercise for greater than or equal to 4 hours a week, and greater than or 
equal to 4 days a week, at a high intensity.  They were between the ages of 50 and 80 
years old. Their BMI was required to be less than 30 and they had to be a non-smoker 
(for greater than 5 years). All participants were free of history of heart attack, stroke, lung 
disease, chronic obstructive lung disease, peripheral vascular disease, heart disease, 
anemia, liver disease, kidney disease and diabetes. Additionally participants were not 
controlling high blood pressure with the use of a prohibited medication (see attached list.) 
Participants were not taking any of the prohibited medications on the attached list at the 
time of the study.  Women participants were post-menopausal for greater than or equal to 
2 years, and had not used hormone therapy in the last year. All participants had to be able 
to complete a vigorous treadmill test without orthopedic limitations.  Initial phone 
screenings were conducted to verify that participants fit the above criteria. Once a 
participant was determined to fit the criteria, we scheduled baseline testing. 
Experimental Protocol: 
The following experimental protocol was approved by the Internal Review Boards 
of both University of Maryland College Park and University of Maryland Baltimore. 
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Participants completed two days of on-site testing at University of Maryland 
College Park and the Baltimore VA Medical Center. The first testing day was for 
obtaining baseline measurements. The second testing day occurred after the participant 
had completed a ten-day complete cessation of training. In most cases, the subject came 
for baseline testing on a Wednesday, continued their regular training until Saturday, then 
stopped training Sunday through the following Wednesday, when the follow up testing 
took place.  Throughout the period of training cessation, the subject kept a log of their 
weight and attempted to keep it constant. 
Testing Day Procedures: 
On both testing days, the procedures were the same. The participant arrived fasted 
at the University of Maryland College Park in the morning. Before testing commenced, 
the informed consent was explained and reviewed with the participant. Following 
obtaining the signed written consent of the participant, baseline questionnaires were 
completed. Each participant completed a health history and physical activity history 
questionnaire at the baseline visit. At both the baseline and follow-up visit, a screening 
visit data sheet was completed to confirm that the participant had not exercised in the past 
24 hours, had not had any alcohol or vitamins in the past 24 hours, had not had caffeine 
overnight, and had not taken NSAIDs in the past 48 hours. Once the questionnaires were 
completed, the participant had their height and weight measured. Following height and 
weight measurements, the researcher performed a venous blood draw on the participant, 
using aseptic technique, to obtain a 50 mL blood sample. 
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Once the questionnaires and blood draw were completed, the subject was 
transported to the Baltimore VA Hospital for the assessment of flow-mediated dilation 
measurement, VO2 max, and body composition. 
Body Composition: 
Body composition was measured by radiology technicians, using dual energy x-
ray absorptiometry (DEXA) (DXA; Prodigy, LUNAR Radiation Corp). Percent body fat 
was measured and recorded. 
Maximal Oxygen Consumption Testing (VO2 Max) 
VO2 Max testing was conducted using indirect calorimetry (Quark, Cosmed USA), 
during a graded exercise test on a treadmill. Participants walked or ran at a constant 
velocity with grade increasing 2% every two minutes (starting at 0%). The test continued 
until maximal effort or exhaustion was reached. Standard criteria for reaching VO2 max 
were used to determine the endpoint of the test. These criteria included a plateau in VO2, 
with increasing workload and respiratory exchange ratio (RER)  > 1.1. The highest 
oxygen consumption value for a 30 second increment was recorded as VO2 max. Values 
are presented in both absolute (L/min) and relative (ml/kg/min) units. Standard ECG 
monitoring was used throughout the test, and a cardiologist was present. 
Brachial Artery Ultrasound Test (BART) 
BART is a non-invasive test to measure endothelial function by quantifying flow-
mediated dilation (FMD). The subject lay supine during the testing process. Blood 
pressure cuffs were placed on both of the subject’s arms. The cuff on the right arm was 
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used to take heart rate and blood pressure intermittently throughout the test. The cuff on 
the left arm was used for the actual testing. A one lead ECG was also used during the test. 
Once the subject was set up, 2D ultrasound and Doppler images were taken of the 
brachial artery for a baseline measure. The technician located the position on the brachial 
artery which provided the clearest picture and marked that spot. That marked spot was 
then used for all subsequent measures to ensure consistency.  Then the blood pressure 
cuff on the right arm was inflated to 200 mmHg for 5 minutes. After 5 minutes, the cuff 
was released and images and Doppler data were taken to measure the response of the 
brachial artery to the hyperemic stimulus. Although maximum dilation occurs about one 
minute after the release of the cuff, images were taken for fifteen minutes, at one-minute 
intervals, following cuff release FMD was measured in percentage of change in brachial 
artery dilation from baseline to post-cuff release. 
When testing in Baltimore was complete, the subject was transported back to 
College Park and released. On the second visit, the participant was compensated $200 at 
the completion of their participation. 
PBMC Isolation: 
Peripheral blood mononuclear cells (PBMCs), and CD34+ cells were isolated 
from the 50 mL venous blood sample on each visit.  PBMCs were isolated using Ficoll-
based density gradient centrifugation. Briefly, the 50 mL blood sample was divided into 
4, 50 mL conical tubes and diluted at a 1:1 ratio with PBS without Ca+2 and Mg+2. 
Diluted blood was carefully overlaid onto 15 mL of Ficoll. Tubes were centrifuged at 
300g for 30 min with slow acceleration and no brake. Following centrifugation, the 
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plasma was discarded, and PBMCs moved to new tubes. PBS+2%FBS+EDTA was added 
to the PBMCs and this solution was centrifuged for another 7 minutes at 300g. The 
supernatant was then removed and the PBMC pellet from each tube was brought up to 
~2mL with PBS+2%FBS and combined into a single round-bottom tube. The sample was 
then centrifuged for 7 mins at 500g. The supernatant was removed and the pellet was 
brought up to 2mL with PBS+2% FBS. A 1:20 dilution of PBMCs and acetic acid/3% 
methylene blue was made and a PBMC count was performed using a hemocytometer. 
CD 34+ Isolation: 
CD 34+ cells were isolated from the PBMC sample using immunomagnetic 
selection (Stemcell Technologies) according to manufacturer’s instructions. Briefly, the 
PBMC solution was brought up to a concentration of 2 x10 8 cell/ ml. CD34+ antibodies 
were added at 10% of the measured concentration of cells. The sample was then 
incubated with the added antibodies for fifteen minutes at room temperature. Following 
incubation, CD34+ nanoparticles were added to the sample at 10% of the measured 
concentration of cells, and this solution was incubated at room temperature for ten 
minutes. Following incubation, the sample was brought up to a volume of 2500 µl with 
PBS+2%FBS and placed into the selection magnet for 5 minutes. After 5 minutes, the 
supernatant was poured off of the sample, while the tube was still in the magnet. Then the 
sample was removed from the magnet and brought back up to a volume of 2500 µl with 
PBS+2%FBS. The magnet selection procedure was then repeated a second time. After 2 
magnet incubations and pours, the sample was brought up to 2mL with PBS+2% FBS, 
and a count of CD34+ cells was performed using a hemocytometer. Purity of the 
proposed isolation protocol was measured during optimization by fluorescent activated 
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cell sorting (FACS) to ensure purity consistent with the literature. Each researcher 
involved in the project had their purity tested using FACS before they began testing 
experimental samples. 50% purity of CD34+ isolation was expected, utilizing comparable 
methods (Jenkins et al 2011). 
ROS/NO Assay 
Following isolation and count of the CD34+ cells, samples were centrifuged at 
500 x g for seven minutes. The supernatant was poured off, and the sample was brought 
up to 250 µl with PBS without Ca+2 and Mg+2. 
Phase I: 
Master mixes were created containing 1.5 x 105 CD34+ cells per reaction and 
PBS without Ca+2 and Mg+2 to bring the mix up to 150 µl  per reaction. A clear 96 well 
plate was used to plate 12 wells of CD34+ master mix. The plate was then allowed to 
incubate at 37°C, 5% CO2, for 6 hours. 
Phase II: 
During the last half hour of the incubation, master mixes were created for phase 
II. One master mix contained 2 µM H2DCFDA (for measurement of ROS) and the other 
contained 10 µM DAF-FM (for the measurement of NO).  Both master mixes contained 
PBS without Ca+2 and Mg+2 to achieve the specified concentration of dyes. Following 6 
hours of incubation, the plate was covered in foil and transported to the centrifuge. The 
plate was spun at 500g for 5 mins to pellet the cells. After the spin, the supernatant was 
removed. Half of the cells were treated with H2DCFDA master mix, and half were 
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treated with DAF master mix. All wells were thoroughly mixed. A row of control wells 
was also present including PBS without Ca+2 and Mg+2 only, H2DCFDA master mix 
without cells, and DAF master mix without cells. The plate was covered with foil and 
dyes were allowed to incubate on the cells for 30 minutes. Following incubation, the plate 
was spun again at 500g for 5 mins to pellet the cells, and the supernatant was removed. 
All wells were re-suspended with 150 µl of PBS without Ca+2 and Mg+2 and the plate was 
covered with foil and transported to the plate reader. 
Measurement of Fluorescent Dyes: 
The ROS/NO assay 96 well plate was read using a Multi-mode microplate reader 
(Biotek Synergy H2). The plates were read using the auto-gain set up at 535nm 
(appropriate for both H2DCFDA and DAF-FM). Measurements of fluorescence were 
saved for analysis. 
mRNA Expression: 
RNA Isolation: 
Any CD34+ cell sample that was not used for the ROS/NO assay was spun down 
to form a pellet, then dissolved in Trizol, and frozen at -80° C for RNA isolation at a later 
date. When the RNA was isolated, the samples were thawed, transferred to 2 mL 
Eppendorf tubes, and vortexed briefly. 200 µl of chloroform was added to each sample, 
the tubes were inverted, and then placed in the rotator for ten minutes. After 10 minutes, 
samples were centrifuged for 12 minutes at 4°C at 12,000g. After centrifugation, we 
carefully removed 50-75% of the upper clear layer and placed it in a second set of 2 ml 
Eppendorf tubes. 500 µl isopropyl alcohol and 5 µl glycogen (coprecipitant) were added 
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to each sample and placed in the rotator for 10 minutes. After ten minutes, the samples 
were spun for 8 minutes at 4°C and 12,000g. After centrifugation, the supernatant was 
removed and 2 mL of ethanol was added to each sample. Samples were vortexed briefly 
to dislodge the pellet, and then incubated at room temperature for 5 minutes. After 
incubation, the samples were centrifuged at 7500g for 5 mins at 4°C. Following the spin, 
the supernatant was removed and the pellet was allowed to air dry for ten to fifteen 
minutes. Once the pellet was clear, TE buffer and the sample were placed on ice and 25 
µl of TE buffer was added to each sample. Samples were then frozen at -80°C until 
reverse transcription was ready to be performed. 
Reverse Transcriptase (RT): 
Samples were thawed and RNA concentration was determined for each sample 
using the spectrophotometer function of the multi-mode microplate reader (Biotek 
Synergy H2). Once RNA concentration was determined, calculations were made to 
determine how much sample was needed for 1 ug of RNA. A master mix was created 
using the RT kit (Applied Biosystems) for each sample, using 2 µl of RT buffer, 0.8 µl of 
1.25 mM dNTP, 2 µl 10x random hexamers, 1 ul of reverse transcriptase. 5.8 µl of master 
mix was added to each well of the reaction plate, and then the required amount of RNA 
solution was added. DH20 was added to bring each well up to 20ul. The reaction plate 
was gently mixed and then spun down before being loaded into the thermocycler (BioRad 
T100). Conditions for RT were 25°C for 10 mins, 37°C for 120 mins, 85°C for 5 seconds 





Semi-quantitative PCR was performed following the RT protocol. qt-PCR was 
performed to quantify mRNA levels of inducible nitric oxide (iNOS), endothelial nitric 
oxide (eNOS), dihydrofolate reductase (DHFR), and GTP cyclohydrolase 1 (GTPCH1).  
mRNA levels were measured for all subjects both before and after the cessation of 
training. 
Gel electrophoresis was performed on each sample using agarose gel. 18s was used as the 
housekeeping gene for this analysis. Following gel electrophoresis, bands were visualized 
under UV light (Kodak) and images were captured for analysis. ImageJ was used to 
quantify the band intensities and to compare mRNA expression between samples. 
Statistics: 
This study design was an intervention design where cessation of training served as 
the intervention. Subjects were studied at baseline and following the intervention period. 
Data were analyzed using a repeated measures ANOVA. The significance level was set at 
p < 0.05. Data for subject demographics are presented as mean + standard deviation and 
data for all other results are presented as means + standard error. Power calculations were 
performed with preliminary data from fresh cell measures to determine the number of 
participants needed. With preliminary data (n=12), NO and ROS levels yielded an 
estimated power of 53% and 73%, respectively. We aimed to test 20 participants, which 
would give us an estimated power of 71% (NO) and 78% (ROS). We tested 19 
participants, but 2 were eliminated due to positive graded exercise test results, one could 
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not be completed due to equipment malfunction, and one subject was eliminated because 



















Chapter 3: Results: 
Subject Characteristics: 
Sixteen “Master Athletes” were studied; 11 men and 5 women.  The women 
participants were all post-menopausal for at least two years and had not taken hormone 
replacement therapy for at least a year. 
Most of the participants were from local running and triathlon clubs.  They were 
healthy and highly fit for their ages, as can be seen in Table 1. Average relative Vo2 max 
(ml/kg/min) for both the men and women exceeded the “superior” range for their ages 
(Heyward 1998). Average body fat percentage, for both men and women, are in the 












Table 1. Subject Characteristics: Age, Maximal oxygen uptake (VO2 max) , Body Fat, 
Body Mass Index (BMI), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure 
(DBP). Mean + standard deviation. 
 Men 
(n = 11) 
Women 
(n = 5) 
Combined  
Group 
(n = 16) 
Age (years) 62.3+8.5 61.3+4.5 62.3+6.9 
VO2 Max 
(ml/kg/min) 
47.8 + 6.4 46.9+4.1 47.3+5.5 
Body Fat (%) 22.7 +5.0 25.3+3.1 23.4+5.5 
BMI (kg/m2) 24.2+2.9 21.1 + 1.3 23.3 + 2.8 
SBP (mmHg) 124.2 +17.1 110 +13.1 119+16 
DBP (mmHg) 70.7+8.6 67.6 + 5.9 70+8 
 
Flow-Mediated Dilation (FMD): 
FMD was measured at the Baltimore VA Medical Center during both visits. There 
was no change in FMD (p= 0.12), with the cessation of training.  At baseline, FMD was 





Figure 1. Average Flow-Mediated Dilation + SEM of the brachial artery at baseline and 
after the cessation of training. 
CD34+ Cell Nitric Oxide Levels 
CD34+ intracellular Nitric Oxide (NO) levels from freshly-isolated cells were 
studied in 15 subjects at baseline and following the ten-day cessation of training. NO was 
measured using DAF and relative fluorescence was analyzed. At baseline, average DAF 
fluorescence (indicating NO) was 27,067 RFUs/5x104 + 3712. Following the ten-day 
cessation of training, average DAF fluorescence was 30,419 RFUs/5x104 + 3228.  The 




Figure 2. Intracellular Nitric Oxide in CD34+ cells at baseline and following the ten-day 
cessation in training. 
ROS 
Differences in CD34+ intracellular ROS from baseline to following the ten-day 
cessation of training were measured using H2DCFDA and relative fluorescence was 
analyzed. At baseline, average H2 fluorescence was 27,699 RFUs/5x104 + 3552. 
Following the ten-day cessation of training, average H2 fluorescence was 32,850 
RFUs/5x104 + 3819. The increase in CD34+ intracellular ROS levels was not significant 





Figure 3. Intracellular Reactive Oxygen Species in CD34+ cells at baseline and 
following a ten-day cessation in training. 
mRNA Expression: 
Subjects’ (n=13) CD34+ cells were frozen the day of isolation and later analyzed 
for mRNA expression. eNOS, iNOS, GCH1, and DHFR were quantified using qt-PCR 
and gel electrophoresis. All mRNA band intensities were normalized to the 18s house-
keeping gene signal. 
eNOS: 
At baseline, eNOS mRNA, normalized to 18s signal, was 0.328 + .06. Following 
the 10 day cessation of training, eNOS mRNA, normalized to 18s signal was 0.148 + .03. 
The observed decrease in eNOS mRNA expression was significant (p = 0.008). (Figure 
4). 




Figure 4.  eNOS mRNA expression at baseline and following a 10 day cessation in 
training 
iNOS 
There was no change in iNOS mRNA expression from baseline to after the ten-
day cessation of training (p = 0.32). At baseline, average iNOS mRNA expression was 
0.7731 + 0.130, and following a ten-day cessation of training, iNOS mRNA was 0.6475 + 
0.10.  (Figure 5). 




Figure 5. CD34+ iNOS mRNA expression at baseline and following a ten-day cessation 
in training 
DHFR 
There was no change in DHFR mRNA expression with a ten-day cessation of 
training (p = 0.915). At baseline, normalized DHFR mRNA expression was 0.567 + 0.04, 
and following a ten-day cessation of training normalized DHFR mRNA was 0.561 + 




Figure 6. DHFR mRNA expression at baseline and following a ten-day cessation of 
training 
GCH1 
There was no change in GCH1 mRNA expression following the 10-day cessation 
in training (p = 0.21). At baseline, the average normalized GCH1 mRNA expression was 
0.8665 + .06. Following a 10-day cessation of training GCH1 normalized mRNA 

















Chapter 4: Discussion: 
Overall, the results of our study did not support our initial hypotheses. We 
hypothesized that a ten-day cessation of training would increase ROS and pathological 
production of NO in CD34+ CACs. However, we observed no changes in ROS and NO 
levels in circulating CD34+ cells following the cessation of training. We also 
hypothesized that a cessation in training would elicit negative changes in the eNOS 
coupling pathway.  mRNA expression for genes related to the eNOS coupling pathway, 
including DHFR, GTPCH1, eNOS and iNOS, were examined. However, there were no 
observed changes in the expression of DHFR, GTPCH1, or iNOS in CD34+ cells with 
the cessation of training. However, there was a significant decrease in CD34+ eNOS 
mRNA expression following the 10-day cessation in training.  Finally, we also expected 
to see changes in FMD after the cessation of training, but no significant changes were 
observed. These findings indicate that a 10-day cessation in exercise training following 
over 20 years of continuous exercise was not sufficient to elicit significant changes in the 
overall nitro-oxidative state of CD34+ cells and functional measures of endothelial 
function. 
Flow Mediated Dilation 
Following the 10-day cessation of training, FMD was numerically lower by 24%, 
however, this change was not statistically significant. FMD is a measure of endothelial 
function and is closely associated with cardiovascular health. FMD has been shown to be 
a valuable tool for analyzing the impact of interventions on the endothelium and equal in 
reliability to comparable invasive measures. (Raitakari 2000) While there is a known age-
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related decline in FMD, exercise training appears to prevent this effect (Black et al 2009).  
When compared to the literature, our master athletes had relatively high FMD values at 
baseline. In an epidemiological study conducted by Yeboah et al (2007), FMD was 
measured in over 2,000 older adults.  The subjects were ages 72-98, so they were 
generally slightly older than our subjects, but representative of the older population as a 
whole. The median FMD measured in these subjects was 3% in the women, and 2.4% in 
the men. As stated above, our subjects’ average FMD was 11.1% at baseline, which is 
much higher than the average older adult. Our results support the theory that exercise 
training helps to prevent age-related decrease in FMD, and that a relatively short-term 
cessation of training may begin to reverse the positive effects of training. Future research 
should examine whether a longer break in training would cause FMD to continue to 
decrease. 
Fresh Cell Fluorescence Measures: NO and ROS 
In contrast to our hypothesis, fresh CD34+ cell measurements of ROS and NO did 
not change significantly with a ten-day cessation of training. Although the changes were 
not significant, some trends were observed. Intracellular NO and ROS were  numerically 
higher by 25% and 26%, respectively following the cessation of training, although these 
changes were again not statistically significant. Intracellular NO is generally believed to 
be beneficial to the vasculature and overall health. NO plays an important and multi-
faceted role within the vasculature as a potent regulator of vascular tone and directly 
impacting endothelial function (Maiorana et al 2003). In CACs, NO also serves an 
equally important regulatory role. NO bioavailability affects the migration and 
proliferation of CACs (Heiss et al, 2010). 
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Exercise training has been shown to positively affect circulating NO 
bioavailability (Maiorana et al 2003) However, our lab previously examined differences 
in intracellular NO and superoxide in CD34+ cells between sedentary and endurance 
trained men.  They found 26% higher intracellular NO and 10% higher intracellular 
superoxide at baseline in the CD34+ cells of the sedentary men (Jenkins et al 2011). 
These findings were surprising, but upon further investigation into possible causal 
pathways, it was determined that the combination of high ROS and high NO levels can 
indicate the pathological production of NO. These findings of increased nitro-oxidative 
stress in C34+ cells in sedentary men provided the rationale for our initial hypotheses. 
eNOS/iNOS 
In the study by Jenkins et al (2011) discussed above, mRNA expression of eNOS 
and iNOS played a large role in explaining their unique findings. Previously, increased 
NO was viewed as generally beneficial, and the higher NO in their sedentary subjects 
was surprising. However, there are several isoforms of NOS and the different isoforms 
produce NO in very different ways. eNOS produces NO within the endothelium and is 
known for its beneficial effects on the vasculature (Forsetermann and Li 2011). eNOS 
also plays an important role in the migration and function of CACs (Ward 2011). iNOS 
has been found to be responsible for the pathological production of NO, which causes 
inflammation and oxidative damage (Sedoris, 2009).  These differences between NOS 
isoforms are especially important when examining intracellular NO to provide context 




Our findings regarding eNOS and iNOS mRNA expression align somewhat with 
the concept of increased nitro-oxidative stress with less physical activity. Our findings 
are novel because of the population studied and the short duration of training cessation. 
The decrease in eNOS mRNA expression after the cessation of training was highly 
significant and underscores the idea that even short breaks in training can negatively 
impact the nitro-oxidative profile of CACs. 
The eNOS “Coupling” Pathway: 
As discussed above, eNOS is responsible for the beneficial production of NO and 
is linked to endothelial and CAC function. Recently, much of the literature relative to 
eNOS has been focused on the eNOS “coupling” pathway. Several recent studies have 
demonstrated that the eNOS coupling pathway is responsible for maintaining nitro-
oxidative homeostasis and facilitates positive benefits for cardiovascular health (Bendall 
et al 2014). When eNOS is coupled, NO is produced and low levels of ROS are 
produced. If eNOS becomes uncoupled, the balance tips in the favor of ROS production 
and pathological levels of NO are produced. In the “uncoupled” state ROS and NO can 
combine to form peroxynitrite (ONOO-), which has a negative impact on the coupling 
pathway and causes eNOS to remain uncoupled. This pathway can be seen in Figure 8 
below (Crabtree et al 2011).  Cofactors in the eNOS coupling pathway have recently been 
discovered to serve a critical role in maintaining nitro-oxidative homeostasis. 
Specifically, BH4 has been identified as the central cofactor involved in eNOS coupling 
(Benson et al 2013). BH4 bioavailability and function has been repeatedly linked to 
endothelial function and protection from cardiovascular disease (Chen et al 2014). 
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Given the current literature on the critical role of eNOS coupling in maintaining 
nitro-oxidative balance, we hypothesized that an increase in CD34+ intracellular NO and 
ROS following the cessation of training would be mediated via the eNOS “uncoupling” 
pathway. We utilized mRNA expression to examine this hypothesis. As discussed 
previously, eNOS mRNA expression in CD34+ CACs was significantly decreased after 
the ten-day cessation in training. We also examined cofactors intimately involved in the 
critical “coupling” of eNOS to elucidate possible mechanisms involved in the changes in 
eNOS expression, i.e. - the mRNA expression of GCH1 and DHFR. 
GCH1 is the rate-limiting enzyme for the de novo synthesis of BH4 (Du et al 
2009). Since BH4 has been shown to be critically important to the coupling of eNOS, we 
hypothesized that GCH1 would decrease following the cessation of training. Despite our 
significant decrease in eNOS observed following the cessation of training, we did not 
observe a significant change in GCH1 mRNA expression in CD34+ cells. Grijalva et al 
(2008) studied the eNOS-coupling pathway and exercise training in Goto-Kasizaki rats. 
In the exercise trained rats there was no significant difference in GCH1 expression, 
despite an increase in eNOS protein.  Alp et al (2003) studied the BH4/eNOS coupling 
pathway in GCH1 transgenic mice. The GCH1 transgenic mice had an over expression of 
GCH1 and exhibited increased endothelial BH4 levels and decreased ROS production 
compared to the wild-type mice (Alp et al 2003). Bendall et al (2005) also used a 
transgenic mouse model to examine the eNOS coupling pathway and the role of GCH1. 
Their GCH1 transgenic mice exhibited greater NO production and preserved eNOS 
coupling (Bendall et al 2005). These studies show that results of research on GCH1 and 
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its role in the eNOS coupling pathway are varied and that its role in the eNOS coupling 
pathway is not fully understood at this point. 
While our results did not support our hypothesis, ours is the first study, to our 
knowledge, to examine GCH1 expression in CACs, specifically CD34+ cells. 
Additionally, there is very little literature on GCH1 expression and its relationship to 
exercise training, and most of the existing research has been done in animal models. We 
formulated our hypotheses based (a) on literature on the eNOS coupling pathway (Figure 
8.) and (b) the mechanism of GCH1 biosynthesis of BH4. However, given the mixed 
results in the literature and our findings in the present study, it is clear that more research 
in humans is needed in this area. 
To further examine the eNOS coupling pathway relative to exercise training, we 
also assessed DHFR mRNA expression in CD34+ CACs. However, DHFR mRNA 
expression was not significantly altered by the ten-day cessation of training. DHFR is 
responsible for mediating the “salvaging pathway” to reduce BH2 back to BH4. Higher 
levels of BH2, in relation to lower levels of BH4, have been linked to decreased 
endothelial function. Takeda et al (2009) studied 163 patients with cardiovascular disease 
and found that higher levels of BH2 in the plasma negatively affected measures of flow-
mediated dilation. They also found that treatment with statins reversed the ratio in favor 
of BH4 and improved FMD (Takeda et al 2009). Crabtree et al (2011) stated that DHFR 
serves a “key role” in coupling eNOS (figure 8).  Due to DHFR’s important involvement 
in the balance between BH2 and BH4, we believed that examining DHFR expression 
levels could provide some insight into the function of the eNOS-coupling pathway in 
CD34+ CACs. Despite a trend towards a decrease in FMD with the cessation in training, 
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we did not see a concurrent decrease in DHFR. A decrease in DHFR would indicate 
decreased activity of the salvaging pathway. Our results do not indicate a clear link 
between the cessation of exercise training and a reduction in DHFR and GCH1 mRNA 
expression in CACs of older endurance athletes. 
 








Chapter 5: Limitations: 
There were several limitations to our study which could have contributed to 
results inconsistent with the literature and our hypotheses. First, we were unable to 
directly measure BH4, BH2, GCH1, or DHFR levels in fresh cells. These compounds are 
typically measured using high performance liquid chromatography (HPLC) in fresh cells.  
The ability to measure BH4,  BH2, GCH1 and DHFR in the freshly isolated CD34+ cells 
could have given us better insight into their involvement in our observed changes in 
eNOS. In this circumstance, the samples we had to work with were already frozen, so 
mRNA expression measurement was the best option. The ability to analyze BH4 and 
BH2 levels directly, rather than upstream mRNA expression, could have allowed us to 
better determine the effects of exercise cessation on the eNOS coupling pathway and 
what mechanistic role BH4 is serving in CD34+ cells. 
There were also some limitations in regards to our fresh cell measures of ROS and 
NO. About halfway through our study, there was some discussion about how the 96-well 
plates that we were using might be affecting our results. We had been using clear plates 
since the beginning of the study, and were then made aware that there may be significant 
cross talk between wells when using clear plates, which could be impacting our 
fluorescence measurements. In an attempt to mitigate this cross talk, we spread out the 
samples on the plate as best we could.  
Another limitation, which is common in human research, was a low number of 
participants. Additionally, since CD34+ cells are already such a small fraction of the total 
CAC population, at times there were not enough cells available after the fresh cell 
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measures for mRNA expression to be measured. Several of our results were approaching 
significance and an increased sample size may have increased our ability to detect 


















Chapter 6: Further Research: 
Further research into the eNOS coupling pathway in CACs should seek to 
measure BH4, BH2, GCH1, and DHFR levels in fresh cells. Direct measurement of the 
ratio of BH4 and BH2 at baseline and following a period of the cessation of training 
could give clear insight into how the eNOS-coupling pathway is functioning. The 
salvaging pathway has been shown to play an important role in vascular health, so being 















Chapter 7: Conclusion: 
 Our results showed that a ten-day cessation in training in older endurance athletes was 
not sufficient to elicit overall changes in flow-mediated dilation or nitro-oxidative stress 
in CD34+ CACs. However, the cessation of training was sufficient to significantly 
decrease eNOS mRNA expression and there was also a trend toward an uncoupled 
oxidative state in circulating CD34+ cells. Our study was the first to examine GCH1 and 
DHFR in CD34+ CACs, and while the results were not significant, there is still much 
research to be done in this area to examine changes in the eNOS-coupling pathway in 
CACs with exercise training. The results of this study illustrate that breaks in training, 
even for relatively short periods of time can impact eNOS levels in CACs and causes a 
trend towards negative changes in endothelial function. Aging, exercise, CAC function, 
and endothelial function are all important factors in cardiovascular disease. Therefore, the 
results of this study contribute to an important and growing body of literature on exercise 
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Cholestyramine    Cholesterol Lowering Drug 
Colestid      Cholesterol Lowering Drug 
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Colestipol     Cholesterol Lowering Drug 
Coreg      β -Blocker 
Corgard     β -Blocker 
Diabinese      Antidiabetes Drug 
DiaBeta     Antidiabetes Drug 
Diovan HCT     Angiotensin II Receptor Antagonist 
plus HCTZ (thiazide diuretic) 
Diucardin     Diuretic (Thiazide) 
Diurese     Diuretic (Thiazide) 
Diuril      Diuretic (Thiazide) 
Dymelor      Antidiabetes Drug 
Enduron     Diuretic (Thiazide) 
Esidrix      Diuretic (Thiazide) 
Exna      Diuretic (Thiazide) 
Ezide      Diuretic (Thiazide) 
Fluvastatin     Cholesterol Lowering Drug 
Furosemide     Diuretic (Thiazide) 
Gemfibrozil     Cholesterol Lowering Drug 
Glimepiride     Antidiabetes Drug 
Glipizide     Antidiabetes Drug 
Glucophage     Glucose Lowering Drug 
Glucotrol     Antidiabetes Drug 
Glynase     Antidiabetes Drug 
Humulin      Glucose Lowering Drug 
Hydrochlorothiazide (HCTZ)   Diuretic (Thiazide) 
HydroDIURIL    Diuretic (Thiazide) 
Hydroflumethiazide    Diuretic (Thiazide) 
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Hydromox     Diuretic (Thiazide) 
Hydro-Par     Diuretic (Thiazide) 
Hygroton     Diuretic (Thiazide) 
Hyzaar      Angiotensin II Receptor Antagonist 
plus HCTZ (thiazide diuretic) 
Iletin      Glucose Lowering Drug 
Indapamide     Diuretic (Thiazide) 
Inderal (Inderide, Inderide LA)  β -Blocker 
Insulin ...     Glucose Lowering Drug 
Kerlone     β -Blocker 
Labetalol     α and β -Blocker 
Lasix      Diuretic (Thiazide) 
Lescol       Cholesterol Lowering Drug 
Lente      Glucose Lowering Drug 
Levatol     β -Blocker 
Lipitor      Cholesterol Lowering Drug 
Lopid      Cholesterol Lowering Drug 
Lopressor     β -Blocker 
Lorelco     Cholesterol Lowering Drug 
Lovastatin     Cholesterol Lowering Drug 
Lozol       Diuretic (Thiazide) 
Maxide     Diuretic (Thiazide) 
Metahydrin     Diuretic (Thiazide) 
Metformin     Glucose Lowering Drug 
Methyclothiazide    Diuretic (Thiazide) 
Metolazone     Diuretic (Thiazide) 
Metoprolol     β -Blocker 
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Mevacor     Cholesterol Lowering Drug 
Micronase     Antidiabetes Drug 
Minipress     α -Blocker 
Mykrox.     Diuretic (Thiazide) 
Nadolol     β -Blocker 
Naturetin      Diuretic (Thiazide) 
Naqua      Diuretic (Thiazide) 
Niacin (vitamin B3 nicotinic acid)  Cholesterol Lowering Drug 
Nicobid, Nicolar    Cholesterol Lowering Drug 
Normodyne     α and β -Blocker 
Novolin     Glucose Lowering Drug 
Oretic      Diuretic (Thiazide) 
Orinase     Antidiabetes Drug 
Penbutolol     β -Blocker 
Pindolol     β -Blocker 
Polythiazide     Diuretic (Thiazide) 
Pravastatin     Cholesterol Lowering Drug 
Pravachol     Cholesterol Lowering Drug 
Prazosin     α -Blocker 
PressTab     Antidiabetes Drug 
Probucol     Cholesterol Lowering Drug 
Propranolol     β -Blocker 
Questran      Cholesterol Lowering Drug 
Quinethazone     Diuretic (Thiazide) 
Renese      Diuretic (Thiazide) 
Saluron     Diuretic (Thiazide) 
Slo-Niacin     Cholesterol Lowering Drug 
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Simvastatin     Cholesterol Lowering Drug 
Spironolactone    Diuretic (Thiazide) 
Sectral      β -Blocker 
Tenormin, (Tenoretic)    β -Blocker 
Timolol     β -Blocker 
Thalitone      Diuretic (Thiazide) 
Tolazimide     Antidiabetes Drug 
Tolbutamide     Antidiabetes Drug 
Tolinase     Antidiabetes Drug 
Toprol      β -Blocker 
Trandate     α and β -Blocker 
Tricholormethiazide    Diuretic (Thiazide) 
Valsartan plus HCTZ    Angiotensin II Receptor Antagonist 
plus HCTZ (thiazide diuretic) 
Velosulin     Glucose Lowering Drug 
Visken      β -Blocker 
Zaroxolyn     Diuretic (Thiazide) 
Zebeta      β -Blocker 
Zocor      Cholesterol Lowering Drug 
Important Note:  If the subject is taking a drug that is not on this list, please refer to a 
reference regarding prescription drugs (e.g., The Pill Book ,10th Edition or on the web at 











Aicher, A., Heeschen, C., Mildner-Rihm, C., Urbich, C., Ihling, C., Technau-Ihling, K., . 
. . Dimmeler, S. (2003). Essential role of endothelial nitric oxide synthase for 
mobilization of stem and progenitor cells. Nat Med, 9(11), 1370-1376. doi: 
10.1038/nm94 
 
Alp , N.J., Mussa, S., Khoo, J., Cai, S., Guzik, T., Jefferson, A., Goh, N., Rockett, K.A., 
Channon, K.M. (2003) Tetrahydrobiopterin-dependent preservation of nitric 
oxide-mediated endothelial function in diabetes by targeted transgenic GTP-
cyclohydrolase I overexpression. J Clin Invest vol. 112 (5) pp. 725-35 
Barnes, A. S. (2012). Obesity and sedentary lifestyles: risk for cardiovascular disease in 
women. Tex Heart Inst J, 39(2), 224-227. 
Bendall, J.K., Alp, N., Warrick, N., Cai, S., Adlam, D., Rockett, K., Yokoyama, M., 
Kawashima, S., Channon, K.M. (2005) Stoichiometric relationships between 
endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and 
eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted 
GTP cyclohydrolase 1 and eNOS overexpression. Circ Res.vol. 97 (9) pp. 864-71 
Bendall, J.K., Douglas, G., McNeill, E., Channon, K.M., Crabtree, M.J. (2014). 
Tetrahydrobiopterin in cardiovascular health and disease. Antioxid Redox Signal 
vol. 20 (18) pp. 3040-77 
Beunza, J. J., Martinez-Gonzalez, M. A., Ebrahim, S., Bes-Rastrollo, M., Nunez, J., 
Martinez, J. A., & Alonso, A. (2007). Sedentary behaviors and the risk of incident 
hypertension: the SUN Cohort. Am J Hypertens, 20(11), 1156-1162. doi: 
10.1016/j.amjhyper.2007.06.007 
Black, M.A., Cable, N.T., Thijssen, D.H.J., Green, D.J. et al. Impact of age, sex, and 
exercise on brachial artery flow-mediated dilatation. (2009) Am J Physiol Heart 
Circ Physiol, 297 (3),H1109-16. 
Blair, S.N., Kohl, H.W., Barlow, C.E., Paffenbarger, R.S., Gibbons, L.W., Macera, C.A. 
(1995). Changes in physical fitness and all-cause mortality. A prospective study 
of healthy and unhealthy men. JAMA vol. 273 (14) pp. 1093-8 
Buttery, L. D., Springall, D. R., Chester, A. H., Evans, T. J., Standfield, E. N., Parums, D. 
V., . . . Polak, J. M. (1996). Inducible nitric oxide synthase is present within 
human atherosclerotic lesions and promotes the formation and activity of 
peroxynitrite. Lab Invest, 75(1), 77-85. 
Chen, D.D., Chen, L.Y., Xie, J.B., Shu, C., Yang, T., Zhou, S., Yuan, H., Chen, A.F. 
Tetrahydrobiopterin regulation of eNOS redox function. Curr Pharm Des (2014) 
vol. 20 (22) pp. 3554-6 
	  
	  51	  
Clarkson, P., Montgomery, H. E., Mullen, M. J., Donald, A. E., Powe, A. J., Bull, T., . . . 
Deanfield, J. E. (1999). Exercise training enhances endothelial function in young 
men. J Am Coll Cardiol, 33(5), 1379-1385. 
Cogle, C.R., Wise, E., Meacham, A.M., Zierold, C., Traverse, J.H., Henry, T.D., Perin, 
E.C., Willerson, J.T., Ellis, S.G., Carlson,  M., Zhao, D.X.M., Bolli, R., Cooke, 
J.P., Anwaruddin, S., Bhatnagar,  A., Cabreira-Hansen, M.G., Grant,  M.B., Lai, 
D., Moyé,  L., Ebert,  R.F., Olson,  R.E., Sayre, S.L., Schulman, I.H., Bosse, R.C., 
Scott, E.W., Simari, R.D., Pepine, C.J., Taylor, D.A. Cardiovascular Cell Therapy 
Research Network (CCTRN) (2014) Detailed analysis of bone marrow from 
patients with ischemic heart disease and left ventricular dysfunction: BM CD34, 
CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res 
vol. 115 (10) pp. 867-74 
Crabtree, M.J., Tatham, A.L., Al-Wakeel, Y., Warrick, N., Hale, A.B., Cai, S., Channon, 
K., Alp, N.J. (2009) Quantitative regulation of intracellular endothelial nitric-
oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry 
and biopterin redox status: insights from cells with tet-regulated GTP 
cyclohydrolase I expression. J Biol Chem vol. 284 (2) pp. 1136-44 
Crabtree, M.J., Hale, A.B., Channon, K.M. (2011) Dihydrofolate reductase protects 
endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin 
deficiency. Free Radic Biol Med. 50 (11) 1639-46. 
Du, J., Wei, N., Xu, H., Ying, G., Vasquez-Vivar, J., Guan, T., Oldham, K.T., Pritchard, 
K.A., Shi, Y. (2009). Identification and functional characterization of 
phosphorylation sites on GTP cyclohydrolase I. Arterioscler Thromb Vasc Biol 
vol. 29 (12) pp. 2161-8 
Dusting, G. J., Fennessy, P., Yin, Z. L., & Gurevich, V. (1998). Nitric oxide in 
atherosclerosis: vascular protector or villain? Clin Exp Pharmacol Physiol Suppl, 
25, S34-41. 
Eskurza, I., Myerburgh, L. A., Kahn, Z. D., & Seals, D. R. (2005). Tetrahydrobiopterin 
augments endothelium-dependent dilatation in sedentary but not in habitually 
exercising older adults. J Physiol, 568(Pt 3), 1057-1065. doi: 
10.1113/jphysiol.2005.092734 
Fleissner, F., & Thum, T. (2011). Critical role of the nitric oxide/reactive oxygen species 
balance in endothelial progenitor dysfunction. Antioxid Redox Signal, 15(4), 933-
948. doi: 10.1089/ars.2010.3502 
Förstermann and Li. (2011) Therapeutic effect of enhancing endothelial nitric oxide 
synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 
vol. 164 (2) pp. 213-23 
Fukai, T. (2007). Endothelial GTPCH in eNOS uncoupling and atherosclerosis. 






Furchgott, R. F., & Vanhoutte, P. M. (1989). Endothelium-derived relaxing and 
contracting factors. FASEB J, 3(9), 2007-2018. 
Green, D. J., Dawson, E. A., Groenewoud, H. M., Jones, H., & Thijssen, D. H. (2014). Is 
flow-mediated dilation nitric oxide mediated?: A meta-analysis. Hypertension, 
63(2), 376-382. doi: 10.1161/HYPERTENSIONAHA.113.02044 
Grijalva, J., Hicks S., Zhao, X., Medikayala, S., Kaminski, P.M., Wolin, M.S., Edwards, 
J.G. (2008). Exercise training enhanced myocardial endothelial nitric oxide 
synthase (eNOS) function in diabetic Goto-Kakizaki (GK) rats. Cardiovasc 
Diabetol. (7)34. 
Hagberg, J. M., Park, J. J., & Brown, M. D. (2000). The role of exercise training in the 
treatment of hypertension: an update. Sports Med, 30(3), 193-206. 
Hambrecht, R., Wolf, A., Gielen, S., Linke, A., Hofer, J., Erbs, S., . . . Schuler, G. (2000). 
Effect of exercise on coronary endothelial function in patients with coronary artery 
disease. N Engl J Med, 342(7), 454-460. doi: 10.1056/NEJM200002173420702 
Heeschen, C., Lehmann, R., Honold, J., Assmus, B., Aicher, A., Walter, D. H., . . 
Dimmeler, S. (2004). Profoundly reduced neovascularization capacity of bone 
marrow mononuclear cells derived from patients with chronic ischemic heart 
disease. Circulation, 109(13), 1615-1622. doi: 
10.1161/01.CIR.0000124476.32871.E3 
Heiss, C., Keymel, S., Niesler, U., Ziemann, J., Kelm, M., & Kalka, C. (2005). Impaired 
progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol, 
45(9), 1441-1448. doi: 10.1016/j.jacc.2004.12.074 
Heiss, C., Schanz, A., Amabile, N., Jahn, S., Chen, Qiumei, Wong, M.L., Rassaf, T., 
Heinen, Y., Cortese-Krott, M., Grossman, W., Yeghiazarians, Y., Springer, M.L. 
(2010) Nitric oxide synthase expression and functional response to nitric oxide are 
both important modulators of circulating angiogenic cell response to angiogenic 
stimuli. Arterioscler Thromb Vasc Biol vol. 30 (11) pp. 2212-8 
Heyward, V.H. (1998). The Physical Fitness Specialist Certification Manual. Advance 
Fitness Assessment & Exercise Prescription. 3rd Edition 
Hill, J. M., Zalos, G., Halcox, J. P., Schenke, W. H., Waclawiw, M. A., Quyyumi, A. A., 
& Finkel, T. (2003). Circulating endothelial progenitor cells, vascular function, 
and cardiovascular risk. N Engl J Med, 348(7), 593-600. doi: 
10.1056/NEJMoa022287 
Hoetzer , G.L., Van Guilder, G.P., Irmiger, H.M., Keith, R.S., Stauffer, B.L., DeSouza, 
C.A. (2007) Aging, exercise, and endothelial progenitor cell clonogenic and 
migratory capacity in men. J Appl Physiol vol. 102 (3) pp. 847-52 
Jenkins, N. T., Landers, R. Q., Prior, S. J., Soni, N., Spangenburg, E. E., & Hagberg, J. M. 
(2011). Effects of acute and chronic endurance exercise on intracellular nitric 
oxide and superoxide in circulating CD34(+) and CD34(-) cells. J Appl Physiol 
(1985), 111(3), 929-937. doi: 10.1152/japplphysiol.00541.2011 
	  
	  53	  
Jenkins, N.T. Witkowski, S., Spangenburg, E.E., Hagberg, J.H. (2009) Effects of acute 
and chronic endurance exercise on intracellular nitric oxide in putative endothelial 
progenitor cells: role of NAPDH oxidase. Am J Physiol Heart Circ Physiol vol. 
297 (5) pp. H1798-805 
Kroncke, K. D., Fehsel, K., & Kolb-Bachofen, V. (1998). Inducible nitric oxide synthase 
in human diseases. Clin Exp Immunol, 113(2), 147-156. 
Maiorana , A., O’Driscoll, G., Taylor, R., Green, D. (2003)  Exercise and the nitric oxide 
vasodilator system. Sports Med vol. 33 (14) pp. 1013-35 
Mangialardi, G., Monopoli, A., Ongini, E., Spinetti, G., Fortunato, O., Emanueli, C., & 
Madeddu, P. (2011). Nitric oxide-donating statin improves multiple functions of 
circulating angiogenic cells. Br J Pharmacol, 164(2b), 570-583. doi: 
10.1111/j.1476-5381.2011.01423.x 
Miyazaki, H., Matsuoka, H., Cooke, J. P., Usui, M., Ueda, S., Okuda, S., & Imaizumi, T. 
(1999). Endogenous nitric oxide synthase inhibitor: a novel marker of 
atherosclerosis. Circulation, 99(9), 1141-1146. 
Murphy, S., Xu, J., Kochanek, K. (2013). Deaths: Final Data for 2010. NVSS, 61(4) 
Pall, M.L. (2009) Do sauna therapy and exercise act by raising the availability of 
tetrahydrobiopterin?. Med Hypotheses vol. 73 (4) pp. 610-3 
Peichev M., Naiyer, A.J., Pereira, D., Zhu, Z., Lane, W.J., Williams, M., Oz, M.C., 
Hicklin, D.J., Witte, L., Moore, M.A., Rafii, S. (2000). Expression of VEGFR-2 
and AC133 by circulating human CD34(+) cells identifies a population of 
functional endothelial precursors. Blood vol. 95 (3) pp. 952-8 
Puddu, P., Puddu, G. M., Zaca, F., & Muscari, A. (2000). Endothelial dysfunction in 
hypertension. Acta Cardiol, 55(4), 221-232. 
Raitakari, O.T., Celermajer, D.S. (2000). Flow-Mediated Dilation. Br J Clin Pharmacol, 
50, 397-404. 
Rush, J. W.E. (2009) Exercising an option to prevent age related decline of vascular BH4 
and uncoupling of eNOS. J Physiol (Lond) vol. 587 (Pt 15) pp. 3755 
Sarto, P., Balducci, E., Balconi, G., Fiordaliso, F., Merlo, L., Tuzzato, G., . . . Latini, R. 
(2007). Effects of exercise training on endothelial progenitor cells in patients with 
chronic heart failure. J Card Fail, 13(9), 701-708. doi: 
10.1016/j.cardfail.2007.06.722 
Scheubel, R. J., Zorn, H., Silber, R. E., Kuss, O., Morawietz, H., Holtz, J., & Simm, A. 
(2003). Age-dependent depression in circulating endothelial progenitor cells in 
patients undergoing coronary artery bypass grafting. J Am Coll Cardiol, 42(12), 
2073-2080. 
Schiffrin, E. L. (2010). Antioxidants in hypertension and cardiovascular disease. Mol 





Sedoris, K.C., Ovechkin, A.V., Gozal, E., Roberts, A.M. (2009). Differential effects of 
nitric oxide synthesis on pulmonary vascular function during lung ischemia-
reperfusion injury. Arch Physiol Biochem. 115 (1) 34-46 
Steiner, S., Niessner, A., Ziegler, S., Richter, B., Seidinger, D., Pleiner, J., . . . Kopp, C. 
W. (2005). Endurance training increases the number of endothelial progenitor 
cells in patients with cardiovascular risk and coronary artery disease. 
Atherosclerosis, 181(2), 305-310. doi: 10.1016/j.atherosclerosis.2005.01.006 
Takeda, M., Yamashita, T., Shinohara, M., Sasaki, N., Takaya, T., Nakajima, K., Inoue, 
N., Masano, H.T., Satomi-Kobayashi, S., Toh, R., Sugiyama, D., Nishimura, K., 
Yokoyama, M., Hirata, K., Kawashimia, S. (2009). Plasma 
tetrahydrobiopterin/dihydrobiopterin ratio: a possible marker of endothelial 
dysfunction. Circ J. 73 (5) 955-62. 
Tanabe, T., Maeda, S., Miyauchi, T., Lemitsu, M., Takanashi, M., Irukayama-Tomobe, 
Y., Yokota, T., Ohmori, H., Matsuda, M. (2003) Exercise training improves 
ageing-induced decrease in eNOS expression of the aorta. Acta Physiol Scand vol. 
178 (1) pp. 3-10 
Thijssen, D. H., Torella, D., Hopman, M. T., & Ellison, G. M. (2009). The role of 
endothelial progenitor and cardiac stem cells in the cardiovascular adaptations to 
age and exercise. Front Biosci (Landmark Ed), 14, 4685-4702. 
Thijssen, D. H., Vos, J. B., Verseyden, C., van Zonneveld, A. J., Smits, P., Sweep, F. C., . 
. . de Boer, H. C. (2006). Haematopoietic stem cells and endothelial progenitor 
cells in healthy men: effect of aging and training. Aging Cell, 5(6), 495-503. doi: 
10.1111/j.1474-9726.2006.00242.x 
Traverse, J. H., Henry, T. D., Pepine, C. J., Willerson, J. T., Zhao, D. X., Ellis, S. G., . . . 
Cardiovascular Cell Therapy Research, N. (2012). Effect of the use and timing of 
bone marrow mononuclear cell delivery on left ventricular function after acute 
myocardial infarction: the TIME randomized trial. JAMA, 308(22), 2380-2389. 
doi: 10.1001/jama.2012.28726 
Traverse, J. H., Henry, T. D., Ellis, S. G., Pepine, C. J., Willerson, J. T., Zhao, D. X., . . . 
Cardiovascular Cell Therapy, R. (2011). Effect of intracoronary delivery of 
autologous bone marrow mononuclear cells 2 to 3 weeks following acute 
myocardial infarction on left ventricular function: the LateTIME randomized trial. 
JAMA, 306(19), 2110-2119. doi: 10.1001/jama.2011.1670 
Van Craenenbroeck E.M., Beckers P.J., Possemiers N.M., Wuyts G.F., Hoymans V.Y., 
Wuyts F., Paelinck B.P., Vrints C.J., & Conraads V.M. (2010). Exercise acutely 
reverses dysfunction of circulating angiogenic cells in chronic heart failure. Eur 
Heart J vol. 31 (15) pp. 1924-34 






Ward, M. R., Thompson, K. A., Isaac, K., Vecchiarelli, J., Zhang, Q., Stewart, D. J., & 
Kutryk, M. J. (2011). Nitric oxide synthase gene transfer restores activity of 
circulating angiogenic cells from patients with coronary artery disease. Mol Ther, 
19(7), 1323-1330. doi: 10.1038/mt.2011.52 
Widder, J. D., Chen, W., Li, L., Dikalov, S., Thony, B., Hatakeyama, K., & Harrison, D. 
G. (2007). Regulation of tetrahydrobiopterin biosynthesis by shear stress. Circ 
Res, 101(8), 830-838. doi: 10.1161/CIRCRESAHA.107.153809 
Wilcox, J.N., Subramanian, R.R., Sundell, C.L., Tracey, W.R., Pollock, J.S., Harrison, 
D.G., Marsden, P.A. (1997) Expression of multiple isoforms of nitric oxide 
synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 
vol. 17 (11) pp. 2479-88 
Witkowski, S., Lockhard, M.M., Jenkins, N.T., Obisesan, T.O., Spangenburg, E.E., 
Hagberg, J.H. (2010). Relationship between circulating progenitor cells, vascular 
function and oxidative stress with long-term training and short-term detraining in 
older men. Clin Sci vol. 118 (4) pp. 303-11 
Xie, H. H., Zhou, S., Chen, D. D., Channon, K. M., Su, D. F., & Chen, A. F. (2010). GTP 
cyclohydrolase I/BH4 pathway protects EPCs via suppressing oxidative stress and 
thrombospondin-1 in salt-sensitive hypertension. Hypertension, 56(6), 1137-1144. 
doi: 10.1161/HYPERTENSIONAHA.110.160622 
Yang, Y.M., Huang, A., Kaley, G., Sun, D. (2009) eNOS uncoupling and endothelial 
dysfunction in aged vessels. Am J Physiol Heart Circ Physiol vol. 297 (5) pp. 
H1829-36 
Yang, J., Ii, M., Kamei, N., Alev, C., Kwon, S. M., Kawamoto, A., . . . Asahara, T. 
(2011). CD34+ cells represent highly functional endothelial progenitor cells in 
murine bone marrow. PLoS One, 6(5), e20219. doi: 
10.1371/journal.pone.0020219 
Yeboah, J., Crouse, J.R., Hsu, F.C., Burke, G.L., Herrington, D.M. (2007) Brachial flow-
mediated dilation predicts incident cardiovascular events in older adults: the 
Cardiovascular Health Study. Circulation vol. 115 (18) pp. 2390-7 
 
 
